Wegovy’s Cardiovascular Benefits May Improve, But Not Transform, Insurance Coverage In Obesity

Novo Nordisk’s obesity drug lowered adverse cardiovascular events by an impressive 20% in a pivotal study. However, payers may still want data on how paying for obesity drugs could lower their overall medical expenses.